EX-12.1 2 ex12_106302012.htm PROGENICS EXHIBIT 12.1 06/30/2012 ex12_106302012.htm

Exhibit 12.1
 
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
 
   
Six Months
Ended
June 30,
    
Years Ended December 31,
  
   
2012
    
2011
    
2010
    
2009
    
2008
    
2007
  
Determination of earnings (loss):
                                    
(Loss) income from operations
   $ (23,806 )   $ 10,381     $ (69,820 )   $ (30,612 )   $ (44,672 )   $ (43,688 )
Add:
                                                
Fixed charges
     153       695       709       555       594       483  
                                                 
Earnings (loss), as adjusted
   $ (23,653 )   $ 11,076     $ (69,111 )   $ (30,057 )   $ (44,078 )   $ (43,205 )
                                                 
Fixed charges:
                                                
                                                 
Estimate of interest within rental expense
     153       695       709       555       594       483  
                                                 
Fixed charges
   $ 153     $ 695     $ 709     $ 555     $ 594     $ 483  
                                                 
Preferred stock dividends
   $ -     $ -     $ -     $ -     $ -     $ -  
                                                 
                                                 
Ratio of earnings (loss) to fixed charges and preferred stock dividends
     *       16       *       *       *       *  
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)
   $ 23,806     $ -     $ 69,820     $ 30,612     $ 44,672     $ 43,688  
_____________________
(1)
For the years ended 2007 through 2010 and for the six months ended June 30, 2012, the Company’s coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.